Skip to main content
PMC home page
Frontiers in Neurology logoLink to Frontiers in Neurology
. 2019 Jun 11;10:604. doi: 10.3389/fneur.2019.00604

Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes

Yuzhen Wei 1,2,†, Haoxiao Chang 1,2,†, Hao Feng 1,2, Xindi Li 1,2, Xinghu Zhang 1,2,*, Linlin Yin 1,2,*
PMCID: PMC6579832  PMID: 31244763

Abstract

Objective: To evaluated the prognostic ability of several serum cytokines in clinically isolated syndrome (CIS) patients regarding second events and conversion to multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD).

Methods: We enrolled 69 CIS patients whose serum samples were collected during the acute phase of the first onset before immunotherapy. Fifteen other non-inflammatory neurological disorder (OND) patients were also included. The serum levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-13, IL-17A, IL-21, IL-23, interferon-γ (IFN-γ), and transforming growth factor beta 1 (TGF-β1) were measured using the human cytokine multiplex assay or ELISA. Patients were seen every 3–6 months. Unscheduled visits occur in case of exacerbations. Clinical measures of disease progression were recorded.

Results: Twenty CIS cases had second events during follow-up at a mean time of 15.3 ± 9.9 months. Serum IL-10 levels were significantly lower in CIS patients who relapsed compared to patients who did not. Low serum IL-10 levels were associated with higher risk and shorter times to second events. In clinical correlations, a significantly higher CSF white blood cells count, number of T2 lesions, and gadolinium-enhancing (Gd+) lesions in baseline MRI were found in the low serum IL-10 level group. Of the 20 relapsed cases, seven converted to MS, and eight converted to NMOSD. No significant differences were found in any cytokine levels between these patients at first onset.

Conclusions: These findings support using serum IL-10 as a biomarker associated with the risk of relapse and the time to second events in patients with CIS. However, serum cytokine levels can not differentiate between the conversion from CIS to MS or NMOSD.

Keywords: interleukin-10, clinically isolated syndrome, biomarker, relapse, multiple sclerosis, neuromyelitis optica spectrum disorder, progression, conversion

Introduction

Idiopathic inflammatory-demyelinating diseases (IIDDs) are monophasic, multiphasic, or progressive disorders characterized by inflammatory demyelination affecting attacks different sites of the central nervous system (CNS) (1). This spectrum represent a broad spectrum of CNS disorders that can be differentiated on the basis of severity, clinical course, lesion distribution, and imaging, laboratory, and pathological findings (1).

Clinically isolated syndrome (CIS) is a term widely used in contemporary neurological practice to describe the first clinical episode in which a patient has symptoms and signs suggestive of an inflammatory demyelinating disorder of the CNS (2). The term “CIS” usually suggests the possibility of multiple sclerosis (MS). However, there can be a considerable overlap between some IIDDs, especially in the initial demyelinating event (IDE). Some CIS will convert to other IIDDs like neuromyelitis optica spectrum disorder (NMOSD), recurrent optic neuritis (ON), and relapsing myelitis during follow-up. More relapses are always associated with poorer recovery of neurological function. The treatment for NMOSD differs from that of MS (3–5). Therefore, early identification of patients at high risk of relapsing activity and prediction of their conversion is crucial for timely treatment escalation or induction therapy (6). Nevertheless, the majority of studies on CIS relapse have focused on its conversion to MS (7). Limited information has been published concerning the evaluation of clinical risk factors for relapse in other multiphasic IIDDs. In addition, very few studies have analyzed the predictive effect of serum cytokine levels on clinical progression (6). A previous study reported the interleukin-8 (IL-8) CSF contents could predict conversion to MS after CIS, suggesting that evaluation of the cytokines in CIS patients may provide useful information for predicting subsequent attacks (6). In the present study, we detected several cytokines in the serum of CIS patients and evaluated their ability to predict second events and conversion from CIS to MS or NMOSD. The associations between serum cytokines levels and clinical findings were also investigated.

Materials and Methods

Patients

Between January 2015 and August 2017, 228 consecutive patients hospitalized in the neurology department of Beijing Tiantan Hospital were diagnosed with CIS. Patients meeting the following conditions were included: (1) the serum samples were collected during the acute phase (< 2 weeks from symptom onset) of the first onset and before any immunomodulatory or immunosuppressive therapy, (2) any infectious or other autoimmune comorbidities did not coexist at the time of sample collection, and (3) patients did not receive immunomodulatory treatment before relapse, or during follow-up time for patients without relapse.

Baseline clinical data including gender, age, routine CSF information (white blood cells [WBC] count, protein level, IgG index, oligoclonal band), MRI information (number of T2 lesions, number of gadolinium-enhancing [Gd+] lesions), and the Expanded Disability Status Scale (EDSS) disability score were recorded. Patients were seen every 3–6 months. Unscheduled visits occurred in case of exacerbations. The EDSS score during each clinic visit and the time to second event were prospectively collected. Relapses were defined as the development of new or recurrent neurological symptoms not associated with fever or infection lasting for at least 24 h. NMOSD and MS diagnoses were made according to the 2015 Revised International Criteria (8) and 2010 McDonald's Diagnostic Criteria (9), respectively.

Fifteen patients with other non-inflammatory neurological diseases (OND) were also enrolled (13 women and two men with a mean age of 40.2 years). The OND group included benign intracranial hypertension (n = 3), cluster headache (n = 3), psychogenic movement disorders (n = 3), normal pressure hydrocephalus (n = 2), benign paroxysmal positional vertigo (n = 2), sleep disturbance (n = 1), and vitamin B12 deficiency (n = 1).

The study was approved by the Ethics Committee of Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China (No. KY2015-031-02), and written informed consent was obtained from all participants.

Biomarker Measurement

The CSF samples were centrifuged and the supernatants were collected and stored at −80°C until analyzed. Samples were tested for the aquaporin-4 antibody (AQP4-Ab) using a cell-based assay (CBA) with live HEK-293 cells transiently transfected with full-length M23-AQP4, as described previously (10). The samples were simultaneously assayed using the MILLIPLEX® MAP Human High Sensitivity Cytokine/Chemokine Panels (Cat. Nos. HCYTOMAG-60K, HCYP2M AG-62K; Merck KGaA, Darmstadt, Germany) for the following nine cytokines: IL-2, IL-4, IL-6, IL-10, IL-13, IL-17A, IL-21, IL-23, and IFN-γ. In addition, the levels of TGF-β1 were measured by ELISA (EHC107b.96, NeoBioscience, Shenzhen, China). All samples were assayed in duplicate and all testing was performed according to the manufacturer's protocols and in a manner that was blinded to diagnoses or clinical presentations.

Statistical Analysis

Statistical analysis was conducted using SPSS 22.0 (International Business Machines Corporation, Chicago, IL, USA). Data were presented as the mean ± SD. Continuous data were compared with the non-parametric Mann–Whitney test. Categorical data were compared with the chi-square or Fisher's exact test. Receiver operating characteristic (ROC) curve analyses were used to determine the best cut-off value based on serum IL-10 levels and CSF WBC count. Univariate and multivariable Cox proportional hazard regression models were used to evaluate the association between serum IL-10 levels and the time to relapse, including the following as covariates: sex and age at the time of the initial demyelinating event, serum IL-10 levels, CSF WBC count, the presence of oligoclonal bands, number of T2 lesions on the initial brain and spinal cord MRI, presence of Gd+ lesions, and EDSS during the first attacks. Dependent variables were first tested in a univariate analysis and included in a multivariate model at a threshold of 0.2 (Wald test) when found to be significant. The time from the initial demyelinating event to relapse was estimated by Kaplan–Meier survival analyses. Log-rank tests were used to compare survival data between low and high serum IL-10 levels. A two-tailed Spearman's rank correlation coefficient was used to ascertain the associations. The significance level was established at p < 0.05.

Results

Patient Characteristics

A total of 69 patients were included in the study. The patient screening process is shown in Figure 1. The average age at first-onset was 41.6 ± 14.7 years. The majority of patients had a monoregional onset (n = 46, 66.7%). Of all 69 patients, the affected regions were as follows: optic nerve, 16 (23.2%) patients; brainstem, 21 (30.4%) patients; spinal cord, 43 (62.3%) patients; and cerebrum, 20 (29.0%) patients. No patients were positive for AQP4-Ab in serum when the first attacks occurred. All patients received corticosteroids during acute relapse after serum samples were collected. The mean follow-up time of patients with CIS was 23.3 ± 8.2 months. The median follow-up time was 23.1 (9.5–39.9) months. There was at least 1 year of follow-up for 91.3% (n = 63) of patients and 2 years for 46.4% (n = 32). Of 69 patients, 20 (29.0%) had second events during follow-up at a mean time of 15.3 ± 9.9 months. Characteristics of CIS patients who relapsed during follow-up are presented in Supplementary Table S1. The baseline characteristics of patient with relapse (R) and non-relapse (NR) during follow-up are detailed in Table 1. CIS-R did not differ from CIS-NR in any analyzed parameters, except for differences in the CSF WBC count (13.3 ± 14.3 vs. 9.7 ± 16.8, p = 0.041). Of 20 CIS-R patients, seven converted to MS according to the 2010 McDonald's Diagnostic Criteria; eight converted to NMOSD according to the 2015 Revised International Criteria; three patients were diagnosed with relapsing myelitis; one with relapsing brainstem encephalitis; and one with tumefactive demyelination. Of the eight NMOSD patients, only one patient was positive for serum AQP4-Ab at relapse.

Figure 1.

Figure 1

Open in a new tab

Patient screening process. From Jan. 2015 to Aug. 2017, 228 consecutive patients with clinically isolated syndromes (CIS) were hospitalized in our department. After excluding 159 patients who did not meet the inclusion criteria, we finally included 69 patients.

Table 1.

Characteristics of the patients with clinically isolated syndromes (CIS).

Clinical characteristics CIS-NR (n = 49) CIS-R (n = 20) p-value
Sex ratio (F/M) 31/18 13/7 0.892
Age, years, mean (SD) 41.7 (14.2) 41.2 (16.1) 0.895
Onset location, n (%)
Monoregional 33 (67.3) 13 (65.0) 0.851
Polyregional 16 (32.7) 7 (35.0) 0.851
Onset location, n (%)
Optic nerve 14 (28.6) 2 (10.0) 0.179
Spinal cord 29 (59.2) 14 (70.0) 0.400
Cerebrum 13 (26.5) 7 (35.0) 0.482
Brainstem 14 (28.6) 7 (35.0) 0.599
EDSS, mean (SD) 3.9 (1.5) 4.4 (1.5) 0.225
CSF analysis at attack
CSF WBC count, mean (SD), /ul 9.7 (16.8) 13.3 (14.3) 0.041*
CSF protein level, mean (SD), mg/dl 35.6 (19.7) 37.3 (20.8) 0.672
CSF IgG index, mean (SD) 1.0 (1.5) 0.8 (1.0) 0.197
Positive oligoclonal bands, n (%) 24 (49.0) 13 (65.0) 0.226
Follow-up time, mean (SD), months 22.4 (7.9) 25.7 (8.5) 0.111
Open in a new tab

Continuous variables were shown as the mean (SD), and categorical variables were described as percentages. CIS-NR, CIS patients who did not relapse during follow-up; CIS-R, CIS patients who relapsed during follow-up; F, female; M, male; EDSS, Expanded Disability Status Scale; CSF, cerebrospinal fluid; WBC, white blood cell;

*

p < 0.05.

Serum IL-10 Levels Are Lower in CIS Patients Who Relapse During Follow-Up

First, we compared serum cytokines levels between the entire cohort of CIS patients and control subjects with OND. The IL-23, IL-10, and TGF-β1 levels were significantly higher in patients with CIS than in patients with OND (p = 0.015, p < 0.001, and p = 0.022, respectively; Figures 2A–C). No significant differences were found in IL-2, IL-4, IL-6, IL-13, IL-17A, IL-21, and IFN-γ levels between CIS and OND patients.

Figure 2.

Figure 2

Open in a new tab

Cytokine levels in serum of patients with clinically isolated syndrome (CIS) and other non-inflammatory neurological diseases (OND). (A) Patients with CIS had significantly higher levels of serum IL-23 than those with OND (p = 0.015). (B) The serum IL-10 levels in CIS were significantly higher than in OND (p < 0.001). (C) The serum TGF-β1 levels in CIS were significantly higher than in OND (p = 0.022). (D) The serum IL-10 levels in CIS patients who relapsed (CIS-R) were significantly lower than in patients who did not relapse (CIS-NR) during follow-up (p = 0.001). *p < 0.05 and **p < 0.01 represent statistical significance using the Mann-Whitney U-test.

Further stratification of the CIS group revealed that only serum IL-10 levels were significantly lower in patients with CIS who relapsed during follow-up compared to patients who did not (p = 0.001; Figure 2D).

Low Serum IL-10 Levels Are a Predictor of Relapse for CIS Patients

ROC analysis showed that the areas under the ROC curve (AUC) for serum IL-10 were significant for relapse (AUC = 0.77; 95% confidence interval[CI] 0.65–0.89; p = 0.001; Supplementary Figure 1A). An IL-10 value of 1.3 pg/ml was determined to be the optimal cut-off point for predicting patient relapse. The sensitivity and specificity of this cut-off were 0.700 and 0.755, respectively and a total of 26 CIS patients (37.7%) had IL-10 levels below the cut-off point. The risk of relapse was higher in patients with lower serum IL-10 levels. There was a significantly higher proportion of patients with clinical relapses during follow-up among the low IL-10 group (IL-10 < 1.3 pg/ml) than among the high IL-10 group (IL-10 ≥ 1.3 pg/ml) (70.0 vs. 30.0%, p < 0.001; Figure 3A).

Figure 3.

Figure 3

Open in a new tab

Low serum IL-10 levels are a predictor of relapse for clinically isolated syndrome (CIS) patients. (A) There was a significantly higher proportion of patients with clinical relapse (R) during follow-up among low IL-10 (<1.3 pg/ml) CIS patients than among high IL-10 (≥1.3 pg/ml) CIS patients (70.0 vs. 30.0%, p < 0.001). (B) Kaplan–Meier curves show that the time to first relapse was shorter in CIS patients with low serum levels of IL-10 (log-rank, p = 0.001).

The CSF WBC cut-off value was also determined by ROC analysis to be 5.5/ul (AUC = 0.66, 95% CI 0.51–0.81, p = 0.042; Supplementary Figure 1B).

Table 2 shows the results of the univariate and multivariable Cox regression models throughout the entire follow-up. In the univariate analysis, serum IL-10 < 1.3 pg/ml (hazard ratio [HR] = 4.36, p = 0.003), CSF WBC count >5.5 /ul (HR = 3.80, p = 0.010), and Gd+ lesions presence in baseline MRI (HR = 8.60, p = 0.036) were associated with an increased risk of relapse. In the multivariate analysis, only the serum IL-10 < 1.3 pg/ml (HR = 2.85, p = 0.045) was predictive of relapse.

Table 2.

Cox regression models containing univariate and multivariate analyses of factors related to the time to relapse.

Variable Univariate analysis HR (95% CI) p Multivariate analysis HR (95% CI) p
Sex 1.01 (0.40–2.54) 0.979
Age 1.00 (0.97–1.03) 0.939
Serum IL-10 < 1.3 pg/ml 4.36 (1.67–11.42) 0.003 2.85 (1.02–7.95) 0.045
CSF WBC count >5.5/ul 3.80 (1.37–10.46) 0.010 1.92 (0.64–5.78) 0.247
Presence of CSF OCBs 0.59 (0.23–1.48) 0.259
Baseline Gd+ MRI 8.60 (1.15–64.35) 0.036 5.87 (0.76–45.1) 0.089
MRI T2 lesions 1.00 (0.95–1.06) 0.938
EDSS 1.16 (0.87–1.54) 0.310
Open in a new tab

HR, hazard ratio; CI, confidence interval; CSF, cerebrospinal fluid; WBC, white blood cell; OCBs, oligoclonal bands; Gd+, gadolinium enhancement; EDSS, Expanded Disability Status Scale.

Low Serum IL-10 Levels Are Associated With a Shorter Time to a Second Event

We next examined the time to relapse in patients with high and low serum IL-10 levels using Kaplan–Meier survival analysis. As depicted in Figure 3B, low serum IL-10 levels were associated with a shorter time to a second event (log-rank, p = 0.001).

Correlations of Serum IL-10 Levels With Clinical and Laboratory Data

Comparing the low IL-10 and high IL-10 groups, we found significantly higher counts of CSF WBC, T2 lesions, and Gd+ lesions in baseline MRI in the low IL-10 group than those of the high IL-10 group (p = 0.035, p = 0.036, and p = 0.049, respectively; Figure 4). No significant differences were observed between the two groups in sex, age, CSF protein level, IgG index, or EDSS during the first-onset and last follow-up.

Figure 4.

Figure 4

Open in a new tab

Positive correlations between serum IL-10 levels and clinical and laboratory data. Compared to the high IL-10 group, we found a significantly higher cerebrospinal fluid (CSF) white blood cells (WBC) count (p = 0.035) (A), number of T2 lesions (p = 0.036) (B), and number of gadolinium-enhancing (Gd+) lesions in baseline MRI (p = 0.049) (C) in the low IL-10 group. *p < 0.05 represent statistical significance in the Mann-Whitney U-test.

We also examined correlations between serum IL-10 levels and the clinical and laboratory findings (i.e., other detected cytokines levels, CSF-WBC count, protein level, and IgG index, number of T2 and Gd+ lesions, and EDSS scores during attacks and remission) using the Spearman rank correlation test. However, we were unable to find any significant correlations between serum IL-10 levels and these data.

Conversion to MS and NMOSD

The baseline characteristics of CIS patients who converted to NMOSD (CIS-N) and MS (CIS-MS) are summarized in Table 3. The CIS-N group had more patients with longitudinally extensive transverse myelitis than the CIS-M group (62.5 vs. 0.0%, p = 0.026). There were no significant differences in other baseline variables between the two groups.

Table 3.

Characteristics of three groups of clinically isolated syndromes (CIS) patients who relapsed during follow-up.

Clinical characteristics CIS-N (n = 8) CIS-M (n = 7) CIS-O (n = 5)
Sex ratio (F/M) 7/1 4/3 2/3
Age at onset, mean (SD), years 41.3 (10.3) 36.0 (20.6) 48.2 (17.5)
Onset location, n (%)
Optic nerve 0 (0.0) 2 (28.6) 0 (0.0)
Spinal cord 7 (87.5) 4 (57.1) 3 (60.0)
≥3 vertebral segments 5 (62.5) 0 (0.0) 2 (40.0)
Cerebrum 1 (12.5) 5 (71.4) 1 (20.0)
Brainstem 3 (33.3) 3 (42.9) 1 (20.0)
Number of T2 lesions, median (range) 1.5 (1–8) 5.0 (1–15) 1.0 (1–4)
Gd+ MRI, n (%) 8 (100.0) 6 (85.7) 5 (100.0)
EDSS, mean (SD) 4.9 (1.5) 4.0 (1.5) 4.1 (1.6)
CSF analysis at onset
CSF WBC count, mean (SD), /ul 16.8 (21.1) 12.1 (7.8) 9.4 (7.3)
CSF protein level, mean (SD), mg/dl 41.5 (25.2) 30.4 (18.3) 40.2 (17.5)
CSF IgG index, mean (SD) 1.1 (1.5) 0.7 (0.4) 0.7 (0.3)
Positive oligoclonal bands, n (%) 3 (37.5) 6 (85.7) 4 (80.0)
Interval to second episode, mean (SD), months 14.1 (10.7) 15.3 (9.6) 21.1 (9.4)
Open in a new tab

CIS-N, CIS patients who converted to neuromyelitis optica spectrum disorder (NMOSD); CIS-M, CIS patients who converted to multiple sclerosis (MS); CIS-O, CIS patients who relapsed without converted to MS or NMOSD; F, female; M, male; Gd+, gadolinium enhancement; EDSS, Expanded Disability Status Scale; CSF, cerebrospinal fluid; WBC, white blood cell.

No significant differences were found in any cytokine levels between CIS patients who converted to NMOSD and those who converted to MS.

Discussion

Prospective studies demonstrate that 60–70% of CIS patients develop a second clinically evident demyelinating event within 20 years (11, 12) and will, therefore, be diagnosed with clinically definite MS (CDMS), NMOSD, recurrent ON, relapsing myelitis, or other disorders. The identification of factors influencing the risk of relapse and conversion is important to effectively determine prognoses, thus directing early intervention strategies. This also carries the potential to further our understanding of the biological mechanisms driving these IIDDs. In this study, we examined several serum cytokines levels in CIS patients during the acute phase of their first onsets and prior to any immunomodulatory or immunosuppressive therapy. We found that serum IL-10 levels were lower in CIS patients who relapsed during follow-up and low serum IL-10 levels were a predictor of second clinically evident demyelinating events. However, among the serum cytokines detected, none could differentiate between the conversion from CIS to MS or NMOSD

As a key immunosuppressive cytokine, IL-10 is expressed by cells of the innate and the adaptive immune system, including dendritic cells (DCs), macrophages, mast cells, natural killer (NK) cells, eosinophils, neutrophils, CD4 and CD8 T cells, and B cells [reviewed in (13–15)]. IL-10 plays a crucial role in preventing inflammatory and autoimmune pathologies, by blocking the production of pro-inflammatory cytokines and hindering the capacity of myeloid cells to efficiently activate T cells (13, 14, 16, 17). Thus, IL-10 prevents excessive tissue damage caused by bacterial and viral infections as well as regulates and represses proinflammatory responses. The production of IL-10 by T cells is considered a hallmark of a subset of regulatory T (Treg) cells that inhibit or dampen immune responses (18, 19). IL-10 is associated with many autoimmune diseases. Blocking the IL-10 pathway in mice causes spontaneous development of inflammatory bowel disease (IBD) (20). Patients with genetic defects in the IL-10/IL-10R pathway develop severe early-onset colitis that can be healed by transplanting IL-10/10R-sufficient stem cells (21). A high IL-10 serum level is maintained during the early phase of remission in some human ulcerative colitis patients, whereas C-reactive protein and IL-6 serum levels return to normal during remission after an increase during the acute phase (22). This indicates that IL-10 plays an important role of maintaining normal immune tolerance of the intestine and inhibiting the autoimmune response of IBD. Similar to its functions in IBD, IL-10 also exerts protective functions during liver inflammation (23, 24).

In autoimmune diseases of the CNS, patients with MS and NMO had higher IL-10 levels in serum and CSF than those of patients with OND or healthy controls (25–27). A reduction in IL-10 producing B cells was found in relapsing-remitting MS (RRMS) patients experiencing relapse compared with patients in remission (28). MS patients infected with helminths displayed an increase in IL-10 producing CD19+CD1dhi B cells as well as a better clinical outcome (29). In line with these results, our study also found that serum IL-10 levels were increased in patients with CIS compared to that of patients with OND. Our study also demonstrated for the first time that low serum IL-10 levels were associated with a higher risk of relapse for CIS patients and shorter time to second events. Regarding clinical correlations, a significantly higher CSF WBC count, number of T2 lesions, and number of Gd+ lesions in baseline MRI were found in the low serum IL-10 levels group. One possibility is that, as a key immunosuppressive cytokine, a decrease in IL-10 may contributes to an imbalance of pro-inflammatory and anti-inflammatory factors (30, 31). The relative predominance of proinflammatory factors leads to an increased inflammatory activity as evidenced by a higher CSF WBC count, greater number of lesions, and earlier disease reactivation (32). Another possibility is that low IL-10 is the consequence, rather than the cause, of more severe inflammation and a more aggressive disease. A low IL-10 level, high WBC count, and greater number of lesions are all indicators of a severe immune response and high risk of conversion. It is important to identify the role of IL-10 in CIS onset and the recurrence process, not only to further our understanding of its pathogenesis, but also because it has practical implications for therapy. When applied with appropriate localization, amounts, and timing, IL-10 can completely protect animals from experimental autoimmune encephalomyelitis (EAE) (33). Some of the classical disease-modifying therapies (DMTs) for MS, such as Interferon-β, Fingolimod, and Glatiramer, have an effect in increasing anti-inflammatory cytokines especially IL-10 (34, 35). Drugs are currently being developed that offer major therapeutic effects by enhancing the production of IL-10. Among these, the ABP dendrimer is most noteworthy. The efficacy of the ABP dendrimer has been evaluated in both preventive and curative therapeutic protocols in EAE mouse models and it was shown to be as efficacious as the current gold standard, Fingolimod (36, 37). These drugs may provide new therapeutic approaches for the treatment of CIS patients, but their clinical effectiveness, safety, and suitability for NMOSD patients remains to be further investigated.

In 85% of patients who later develop MS, clinical onset occurs with CIS. The term CIS usually suggests the possibility of MS. Neuromyelitis optica (NMO) is considered a severe variant of MS, and it is frequently misdiagnosed as such. The discovery of AQP4-Ab in 2004 greatly contributed to differentiating CIS from MS, revolutionizing diagnosis (38, 39). In 2015, the term “NMOSD” was adopted and it is classified into two types: AQP4-Ab-positive and AQP4-Ab-negative NMOSD (8). With improvements to our understanding of NMOSD, the conversion from CIS to NMOSD has drawn greater concern and attention (40). It has been suggested that NMO has a predilection for non-white. The proportion of NMO among IIDDs of the CNS is 1.2% in Italy, 1–2% in the USA, and 39.3% in Thailand (41, 42). The ratios of NMO/NMOSD to MS in Asia are much higher than those in Western countries. The ratios were 41% in Malays, and 63% in Chinese (41–44). However, data on the proportion and regional differences of conversion from CIS patients to NMOSD are still lacking. In the present study, of the 69 CIS patients, there were seven converted to MS and eight converted to NMOSD after a mean follow-up of 23.3 ± 8.2 months. There were more CIS patients converted to NMOSD than MS. But given the relatively small sample size and short follow-up duration in our study, larger scale prospective studies with long-term follow-up are expected to address these issues.

As CIS can convert to different IIDDs, future research is necessary for investigating factors affecting the conversion of these disorders and their predictive biomarkers. In this study, we found no significant differences in any cytokine levels between CIS patients who converted to NMOSD compared with those who converted to MS. However, in previous researches, the serum cytokine profiles of NMOSD patients were distinct from those with MS (25, 26, 45–47). This may be because the majority of these studies have analyzed a combination of treated and untreated patients, patients with first onset and recurrence, or patients with and without AQP4-Ab. Very few studies compared AQP4-Ab-positive and AQP4-Ab-negative NMOSD patients in their analysis. Our previous study showed that differences in cytokines at first-onset was more significant in AQP4-Ab-positive NMOSD patients than in AQP4-Ab-negative NMOSD patients, when compared with MS patients (27). Although the contrast found in our study may be due to a small sample size and differences in patient characteristics, whether cytokine levels change during the conversion from CIS to NMOSD or MS remains an important issue that should be examined in future research.

None of the CIS patients were positive for AQP4-Ab in serum at the first attack. This may be because AQP4-Ab-positive patients can be diagnosed with NMOSD as only one core clinical characteristic is needed, so few patients diagnosed with CIS remain. AQP4-Ab is known to be pathogenic and can be detected as early as a decade prior to the onset of the disease (48–50). Several independent studies found a higher frequency of AQP4-Ab in patients with relapsing NMO than in patients with monophasic NMO (51, 52). This implies that AQP4-Ab does not turn positive at some point after disease onset (53). Therefore, patients negative for AQP4-Ab at first-onset may remain negative when relapsed. In the present study, of the eight patients who converted to NMOSD during follow-up, serum AQP4-Abs remained negative in seven patients, while the serum antibody of one patients turned positive at relapse. The inconsistency in the present case may be because the CBA tests sensitivity ranges from 57 to 91% (54, 55), and a false negative result may occur. Another possibility is that two attacks in this case belonged to different disease processes. As a result, it is highly important to improve the sensitivities of the detection methods and to recheck AQP4-Ab in patients with recurrence.

Some limitations in our study need to be addressed. Because our patient cohort was small and derived from a single university hospital, and the follow-up duration was short, the results should be verified in larger-scale, multicenter studies with long-term follow-up. We could not adequately analyze the serial change in serum cytokine levels after first onset, and whether this change would affect the risk of recurrence and conversion could not be determined. Also the anti-MOG antibodies were not measured in our study. Further studies are expected to address these issues. In addition, it is necessary to investigate the role of the IL-10 pathway in CIS pathogenesis and therapeutic strategies.

Conclusions

The aggregate results from this study confirm that serum IL-10 serves as a prognostic biomarker associated with the risk of relapse and the time to second events in CIS patients. We propose that serum IL-10 levels should be measured in CIS patients to identify those individuals with a high risk of relapse. This result suggests that reinforcement of the IL-10 pathway may be a promising therapeutic strategy for patients at high risk of relapse.

Ethics Statement

The study was approved by the Ethics Committee of Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China (No. KY2015-031-02), and written informed consent was obtained from all participants.

Author Contributions

YW, XZ, and LY conceived and designed the study. HC performed the MILLIPLEX® map human High Sensitivity Cytokine Panels tests and ELISA tests. YW, HF, and XL participated in evaluating the EDSS scores of patients and collecting blood samples. YW performed the statistical analysis. XZ and LY revised the manuscript. All authors reviewed the final manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. This work was supported by Beijing Municipal Science & Technology Commission (No. Z141107002514124), Beijing Natural Science Foundation (No. 7162208) and Beijing Health and Technical Personal of High-level Plan (No. 2014-3-052).

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.00604/full#supplementary-material

Click here for additional data file. (19.9KB, docx)
Click here for additional data file. (121.8KB, docx)

References

  • 1.Canellas AR, Gols AR, Izquierdo JR, Subirana MT, Gairin XM. Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology. (2007) 49:393–409. 10.1007/s00234-007-0216-2 [DOI] [PubMed] [Google Scholar]
  • 2.Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. (2008) 14:1157–74. 10.1177/1352458508096878 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. (2008) 255:305–7. 10.1007/s00415-007-0730-5 [DOI] [PubMed] [Google Scholar]
  • 4.Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. (2010) 67:1016–7. 10.1001/archneurol.2010.188 [DOI] [PubMed] [Google Scholar]
  • 5.Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. (2012) 18:108–12. 10.1177/1352458511421185 [DOI] [PubMed] [Google Scholar]
  • 6.Rossi S, Motta C, Studer V, Macchiarulo G, Germani G, Finardi A, et al. Subclinical central inflammation is risk for RIS and CIS conversion to MS. Mult Scler. (2015) 21:1443–52. 10.1177/1352458514564482 [DOI] [PubMed] [Google Scholar]
  • 7.Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. (2015) 21:1013–24. 10.1177/1352458514568827 [DOI] [PubMed] [Google Scholar]
  • 8.Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. (2015) 85:177–89. 10.1212/WNL.0000000000001729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Mcdonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. (2001) 50:121–7. 10.1002/ana.1032 [DOI] [PubMed] [Google Scholar]
  • 10.Sato DK, Nakashima I, Takahashi T, Misu T, Waters P, Kuroda H, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. (2013) 80:2210–6. 10.1212/WNL.0b013e318296ea08 [DOI] [PubMed] [Google Scholar]
  • 11.Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. (2008) 131:808–17. 10.1093/brain/awm329 [DOI] [PubMed] [Google Scholar]
  • 12.Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. (2012) 11:157–69. 10.1016/S1474-4422(11)70274-5 [DOI] [PubMed] [Google Scholar]
  • 13.Moore KW, De Waal Malefyt R, Coffman RL, O'garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. (2001) 19:683–765. 10.1146/annurev.immunol.19.1.683 [DOI] [PubMed] [Google Scholar]
  • 14.Saraiva M, O'garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. (2010) 10:170–81. 10.1038/nri2711 [DOI] [PubMed] [Google Scholar]
  • 15.Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. (2011) 29:71–109. 10.1146/annurev-immunol-031210-101312 [DOI] [PubMed] [Google Scholar]
  • 16.Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. (2010) 21:331–44. 10.1016/j.cytogfr.2010.09.002 [DOI] [PubMed] [Google Scholar]
  • 17.Geginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M, et al. The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. Cytokine Growth Factor Rev. (2016) 30:87–93. 10.1016/j.cytogfr.2016.02.003 [DOI] [PubMed] [Google Scholar]
  • 18.Groux H, O'garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. (1997) 389:737–42. 10.1038/39614 [DOI] [PubMed] [Google Scholar]
  • 19.Haringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. J Exp Med. (2009) 206:1009–17. 10.1084/jem.20082238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. (1993) 75:263–74. 10.1016/0092-8674(93)80068-P [DOI] [PubMed] [Google Scholar]
  • 21.Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci. (2011) 1246:102–7. 10.1111/j.1749-6632.2011.06339.x [DOI] [PubMed] [Google Scholar]
  • 22.Mitsuyama K, Tomiyasu N, Takaki K, Masuda J, Yamasaki H, Kuwaki K, et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediat Inflamm. (2006) 2006:26875. 10.1155/MI/2006/26875 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Louis H, Le Moine O, Peny MO, Quertinmont E, Fokan D, Goldman M, et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology. (1997) 25:1382–9. 10.1002/hep.510250614 [DOI] [PubMed] [Google Scholar]
  • 24.Di Marco R, Xiang M, Zaccone P, Leonardi C, Franco S, Meroni P, et al. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity. (1999) 31:75–83. 10.3109/08916939908994050 [DOI] [PubMed] [Google Scholar]
  • 25.Chang KH, Ro LS, Lyu RK, Chen CM. Biomarkers for neuromyelitis optica. Clin Chim Acta. (2015) 440:64–71. 10.1016/j.cca.2014.11.004 [DOI] [PubMed] [Google Scholar]
  • 26.Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e134. 10.1212/NXI.0000000000000134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wei Y, Chang H, Li X, Wang H, Du L, Zhou H, et al. Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6. Neuroimmunomodulation. (2018) 25:215–24. 10.1159/000494976 [DOI] [PubMed] [Google Scholar]
  • 28.Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen Tervaert JW, et al. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J Neuroimmunol. (2011) 239:80–6. 10.1016/j.jneuroim.2011.08.019 [DOI] [PubMed] [Google Scholar]
  • 29.Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol. (2008) 64:187–99. 10.1002/ana.21438 [DOI] [PubMed] [Google Scholar]
  • 30.Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. (2014) 13:668–77. 10.1016/j.autrev.2013.12.004 [DOI] [PubMed] [Google Scholar]
  • 31.Falcao PL, Campos TPR. The role of regulatory T cells, interleukin-10 and in vivo scintigraphy in autoimmune and idiopathic diseases - Therapeutic perspectives and prognosis. Rev Assoc Med Bras. (2017) 63:1090–9. 10.1590/1806-9282.63.12.1090 [DOI] [PubMed] [Google Scholar]
  • 32.Babaloo Z, Aliparasti MR, Babaiea F, Almasi S, Baradaran B, Farhoudi M. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels. Immunol Lett. (2015) 164:76–80. 10.1016/j.imlet.2015.01.001 [DOI] [PubMed] [Google Scholar]
  • 33.Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffman RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med. (1999) 189:1005–10. 10.1084/jem.189.6.1005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Longbrake EE, Cross AH. Effect of multiple sclerosis disease-modifying therapies on B cells and humoral immunity. JAMA Neurol. (2016) 73:219–25. 10.1001/jamaneurol.2015.3977 [DOI] [PubMed] [Google Scholar]
  • 35.Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest. (2017) 127:772–9. 10.1172/JCI85113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Hayder M, Varilh M, Turrin CO, Saoudi A, Caminade AM, Poupot R, et al. Phosphorus-based dendrimer ABP treats neuroinflammation by promoting IL-10-producing CD4(+) T cells. Biomacromolecules. (2015) 16:3425–33. 10.1021/acs.biomac.5b00643 [DOI] [PubMed] [Google Scholar]
  • 37.Fruchon S, Poupot R. The ABP dendrimer, a drug-candidate against inflammatory diseases that triggers the activation of interleukin-10 producing immune cells. Molecules. (2018) 23:E1272. 10.3390/molecules23061272 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. (2004) 364:2106–12. 10.1016/S0140-6736(04)17551-X [DOI] [PubMed] [Google Scholar]
  • 39.Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. (2005) 202:473–7. 10.1084/jem.20050304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Bi CF, Qian HR, Peng LJ, Mao LL, Huang X, Xia DY, et al. The correlation factor analysis for conversion of clinically isolated syndrome to multiple sclerosis and neuromyelitis optica. Zhonghua Nei Ke Za Zhi. (2016) 55:460–5. 10.3760/cma.j.issn.0578-1426.2016.06.012 [DOI] [PubMed] [Google Scholar]
  • 41.Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. (2015) 21:845–53. 10.1177/1352458515572406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol. (2016) 29:222–8. 10.1097/WCO.0000000000000328 [DOI] [PubMed] [Google Scholar]
  • 43.Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. (2011) 76:1589–95. 10.1212/WNL.0b013e3182190f74 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. (2012) 69:1176–80. 10.1001/archneurol.2012.314 [DOI] [PubMed] [Google Scholar]
  • 45.Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. (2010) 16:1443–52. 10.1177/1352458510379247 [DOI] [PubMed] [Google Scholar]
  • 46.Wang H, Wang K, Wang C, Xu F, Qiu W, Hu X. Increased plasma interleukin-32 expression in patients with neuromyelitis optica. J Clin Immunol. (2013) 33:666–70. 10.1007/s10875-012-9837-2 [DOI] [PubMed] [Google Scholar]
  • 47.Wang KC, Lee CL, Chen SY, Chen JC, Yang CW, Chen SJ, et al. Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis. J Interferon Cytokine Res. (2013) 33:58–64. 10.1089/jir.2012.0040 [DOI] [PubMed] [Google Scholar]
  • 48.Nishiyama S, Ito T, Misu T, Takahashi T, Kikuchi A, Suzuki N, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology. (2009) 72:1960–1. 10.1212/WNL.0b013e3181a82621 [DOI] [PubMed] [Google Scholar]
  • 49.Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. (2012) 11:535–44. 10.1016/S1474-4422(12)70133-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Kovacs KT, Kalluri SR, Boza-Serrano A, Deierborg T, Csepany T, Simo M, et al. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: a preliminary study. Mult Scler. (2016) 22:1192–201. 10.1177/1352458515613165 [DOI] [PubMed] [Google Scholar]
  • 51.Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler. (2011) 17:1527–30. 10.1177/1352458511412995 [DOI] [PubMed] [Google Scholar]
  • 52.Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflamm. (2012) 9:14. 10.1186/1742-2094-9-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. (2013) 23:661–83. 10.1111/bpa.12084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J. (2008) 15:99–105. [PubMed] [Google Scholar]
  • 55.Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zephir H, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology. (2013) 80:2194–200. 10.1212/WNL.0b013e318296e917 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (19.9KB, docx)
Click here for additional data file. (121.8KB, docx)

Articles from Frontiers in Neurology are provided here courtesy of Frontiers Media SA

RESOURCES